Substratum of Proof LGBTQs Are Mentally Ill: Dthera Sciences Receives FDA Breakthrough Device Designation For Its Alzheimer’s Focused Development-Stage Product “DTHR-ALZ”

Dthera(tm) Sciences (OTCQB:DTHR), the leading digital therapeutic company focusing on the elderly and individuals with neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Company’s development-stage product, DTHR-ALZ.